Generation and characterization of a human bradykinin receptor B1 transgenic rat as a pharmacodynamic model.
Antagonists of the B1 bradykinin receptor (B1R) offer the promise of novel therapeutic agents for the treatment of inflammatory and neuropathic pain. However, the in vivo characterization of the pharmacodynamics of B1R antagonists is hindered by the low level of B1R expression in healthy tissue and the profound species selectivity exhibited by many compounds for the human B1R. To circumvent these issues, we generated a transgenic rat expressing the human B1R under the control of the neuron-specific enolase promoter. Membranes prepared from whole brain homogenates of heterozygous transgenic rats indicate a B1R expression level of 30 to 40 fmol/mg; there is no detectable B1R expression in control nontransgenic rats. The pharmacological profile of the B1R expressed in the transgenic rat matches that expected of the human, but not the rat receptor. The mapping of the transgene insertion site to rat chromosome 1 permitted the development of a reliable assay for the identification of homozygous transgenic rats. Significantly, homozygous transgenic rats express 2-fold more B1R than heterozygous animals. Autoradiographic analyses of tissue sections from transgenic rats reveal that the B1R is broadly expressed in both the brain and spinal cord. The human B1R expressed in the transgenic rat functions in an in vitro contractile assay and thus has the potential to elicit a functional response in vivo. Using the humanized B1R transgenic rat, an assay was developed that is suitable for the routine evaluation of a test compound's ability to occupy the human B1R in the central nervous system.
Hess
J Fred
JF
Department of Molecular Neurology, Merck Research Lab, WP26A-3000, P.O. Box 4, West Point, PA 19486, USA. fred_hess@merck.com
Ransom
Richard W
RW
Zeng
Zhizhen
Z
Chang
Raymond S L
RS
Hey
Patricia J
PJ
Warren
Lee
L
Harrell
Charles M
CM
Murphy
Kathryn L
KL
Chen
Tsing-Bau
TB
Miller
Patricia J
PJ
Lis
Edward
E
Reiss
Duane
D
Gibson
Raymond E
RE
Markowitz
M Kristine
MK
DiPardo
Robert M
RM
Su
Dai-Shi
DS
Bock
Mark G
MG
Gould
Robert J
RJ
Pettibone
Douglas J
DJ
D000818:Animals; D030801:Animals, Genetically Modified / Q000235:genetics* / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D016466:CHO Cells; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007082:Ileum / Q000187:drug effects / Q000378:metabolism; D008297:Male; D023421:Models, Animal; D010446:Peptide Fragments / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D051381:Rats / Q000235:genetics*; D043783:Receptor, Bradykinin B1 / Q000096:biosynthesis* / Q000235:genetics*
D010446:Peptide Fragments; D043783:Receptor, Bradykinin B1